

(A)
ICOS^HI
T reg
T reg
T reg
(i)
ICOS^LOW
T eff
(ii)
NK cell
NK cell
(B)
(iii)
T reg
T reg
T reg
T reg
NK cell
(iv)
T eff
T eff
T eff
(C)
(v)
T reg
T reg
T reg
T reg
NK cell
NK cell

FIG. 1



Phase 1 Dose Escalation
Completed
Phase 1 Enrichment Cohorts
Ongoing
Phase 2 Expansion
Ongoing
n=4
0.8mg
n=5
2.4mg
n=9
8mg
n=8
24mg
n=7
80mg
n=5
240mg
(i)
n=5
0.8mg+1200mg
n=21**
2.4mg+1200mg
n=21
8mg+1200mg
n=9
24mg+1200mg
n=9
80mg+1200mg
(ii)

FIG. 2




FIG. 3



(A)
PD-L1+ immune infiltrate in TME (%)
100
75
25
20
15
10
5
0
Q1
Q2
Q3
Q4
0
100
200
300
400
500
1000
4000
CD8+ in TME (cells/mm2)
PR+CR
SD
PD
(B)
PD-L1+ on tumour cells in TME (%)
100
75
25
20
15
10
5
0
Q1
Q2
Q3
Q4
0
50
100
150
200
250
350
5000
CD8+ in TME (cells/mm2)
PR+CR
SD
PD

FIG. 4

(A)

Cohort	KY1044 dose (mgs)	Naive/Pre-treated	Patient status	Cancer	TTD (weeks)	BOR
3M	8	Naive	Enrolled	HCC	51.1	SD




FIG. 5



(D)
Relative % to T-lymphocytes (CD3+) at C1D1
TREGRELT
CD4HRELT
CD4MEMRELT
CD8TRELT
CD4NAIVERELT
CD8NAIVERELT
CD8MEMRELT
(vi)
Relative % to all PMBCs at C1D1
TREGRELALL
CD4HRELALL
CD4MEMRELALL
CD8TRELALL
CD4NAIVERELALL
CD8NAIVERELALL
CD8MEMRELALL
TCELLSRELALL
MONOSRELALL
(vii)
Relative % to ICOS+ cells to parent at C1D1
ICOSTREG
ICOSCD4MEM
ICOSCD4H
ICOSTCELLS
ICOSCD8MEM
ICOSCD4NAIVE
ICOSCD8T
ICOSCD8NAIVE
(viii)
(E)
% of CD4MEM (within CD4 cells)
C1D1 (pre-dose)
C1D8
C2D1 (pre-dose)
C2D8
(ix)
% of ICOS CD4MEM (within CD4MEM cells)
C1D1 (pre-dose)
C1D8
C2D1 (pre-dose)
C2D8
(x)

FIG. 5 Cont'd



ICOS FOXP3
PanCK CD8
PD-L1
(A)
(B)
(C)
Screening desert
C2D8 excluded - intra-tumoral
▲ (relevant cell type)

FIG. 6

(A)

Cohort	KY1044 dose (mgs)	Naive/Pre-treated	Patient status	Cancer	TTD	BOR
3M	8	Pre-treated	Off treatment	HCC	27.3	SD

(B)




FIG. 7



(C)
(iv)
PD-L1+ (%)
100
60
20
8
6
4
2
0
Screening
C2D8
(v)
PD-L1+ (%)
100
60
20
8
6
4
2
0
Screening
C2D8
(D)
(vi)
% of CD4MEM
(within CD4 cells)
100
50
0
C1D1 (pre-dose)
C1D8
C2D1 (pre-dose)
C2D8
(vii)
% of ICOS CD4MEM
(within CD4MEM cells)
100
50
0
C1D1 (pre-dose)
C1D8
C2D1 (pre-dose)
C2D8

FIG. 7 Cont'd




ICOS FOXP3
PanCK CD8
PD-L1
(A)
(B)
(C)
Screening excluded - intra-tumoral
▲(relevant cell type)

FIG. 8


(A)
6L KY1044-CT01
5L 5-FU
4L Carboplatin and Paclitaxel/nab-Paclitaxel
3L Cetuximab + Cisplatin
2L Nivolumab
1L Cisplatin + Docetaxel + 5-FU
PR
PD
PR
PD
PD
PR
**
0
5
10
15
Treatment duration (months)




(B)
30%
20%
10%
0%
-10%
-20%
-30%
-40%
-50%
-42%
-42%
Screening
2020-06-05
C3D8
C10D1

FIG. 9

(C)



(D)





FIG. 9 Cont'd

Heavy chain



Light chain




FIG. 10




Heavy chain
germline EVQLVESGGGVVRPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSGINWNGGSTGYADSVKGRFTI
STIM003 .....v...v.....d.d.s.....
CL-71642 .....
CL-74570 .....i.....i.dn.d.....
FW1 CDR1 FW2 CDR2 FW3
germline SRDNAKNSLYLQMNSLRAEDTALYYCARDYYGSGSYYN-YFDYWGQGTLVTVSS
STIM003 .....f.....hvp.....i.....
CL-71642 .....a.....vp.....
CL-74570 .....f.....vp.....
FW3 CDR3 FW4
Light chain
germline EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGT
STIM003 .....r.....d.....
CL-71642 .....
CL-74570 .....
FW1 CDR1 FW2 CDR2 FW3
germline DFTLTISRLEPEDFAVYYCQQYGSSPFTFGPGTKVDIK
STIM003 ....s.....h..dm.....
CL-71642 .....
CL-74570 .....h...n.....
FW3 CDR3 FW4

FIG. 11

Heavy chain



Light chain




FIG. 12